Healthcare
Immunocore Holdings plc(IMCR)
Live Price
Offline$28.66
+0.39% today
1Y Change
-10.81%
Window
Jun 25, 2025 โ Jun 17, 2026
- Market Cap
- $1.41B
- Revenue Growth
- +20.0%
- EPS Growth
- +48.0%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Immunocore Holdings plc (IMCR) is a Healthcare stock with a market cap of $1.41B and listed on NASDAQ. The stock last traded around $28.66 and down 10.8% across the available one-year price window (Jun 25, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +20.0%, EPS growth of +48.0%, a dividend yield of 0.0%. What stands out right now is revenue +20.0%, EPS +48.0%, free cash flow -153.6% with operating margin -10.8% and ROIC -4.9%. Valuation is more restrained than many high-expectation growth names at price/sales 3.8. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines IMCR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+20.0% vs +7.6% peer median
Operating Margin
Below sector median
-10.8% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +20.0% and EPS at +48.0%, with operating margin around -10.8%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +3.7% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | โ | -0.4% | -5.8% | -6.4% |
2026 Feb 25, 2026 | -114.3% | -0.4% | +4.9% | -5.8% |
2025 Nov 6, 2025 | +105.2% | +6.0% | +11.9% | +22.7% |
Benchmark Edge
IMCR vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
IMCR
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
IMCR Max Drawdown
-30.90%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for IMCR and SPY.
Company Overview
Immunocore Holdings plc
NASDAQ Global Select
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
- Leadership
- Bahija Jallal
- IPO Date
- Feb 5, 2021
- Employees
- 493
- Street Address
- 92 Park Drive
- Mailing
- Abingdon, OX14 4RY
- Region
- Abingdon, GB
- Reporting Currency
- USD
- Investor Line
- 44 12 3543 8600
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 3.8
- Price/Book
- 3.7
Growth
- Revenue
- +20.0%
- EPS
- +48.0%
- Free Cash Flow
- -153.6%
Profitability
- Gross Margin
- 98.7%
- Operating Margin
- -10.8%
- Net Margin
- -7.2%
- ROE
- -6.9%
- ROIC
- -4.9%
Balance Sheet
- Debt/Equity
- 0.11
- Current Ratio
- 4.04
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.